Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.

Gene therapy - 1 Mar 2014

Klippel Z K, Chou J, Towlerton A M, Voong L N, Robbins P, Bensinger W I, Warren E H

Abstract excerpt

Adoptive immunotherapy of tumors with T cells specific for the cancer-testis antigen NY-ESO-1 has shown great promise in preclinical models and in early stage clinical trials. Tumor persistence or recurrence after NY-ESO-1-specific therapy occurs, however, and the mechanisms of recurrence remain poorly defined. In a murine xenograft model of NY-ESO-1(+) multiple myeloma, we observed tumor recurrence after...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antigen-Presenting Cells
Share to CD8-Positive T-Lymphocytes

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HLA-A2 Antigen

Share to Immunotherapy

Share to Mice, Inbred NOD

Share to Mice, SCID

Share to Multiple Myeloma

Share to Tumor Escape

Source

Open in PubMed Open full text

Identifiers

PMID: 24451117
DOI: 10.1038/gt.2013.87
PMCID: PMC4040020

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Immune escape from NY-ESO-1-specific T-cell therapy via loss of heterozygosity in the MHC.PMID 24451117Read ↗

Effective NY-ESO-1–specific MHC II–restricted T cell receptors from antigen-negative hosts enhance tumor regressionSemantic proximity Read ↗

Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression.Semantic proximity Read ↗

A rare population of tumor antigen-specific CD4+CD8+ double-positive αβ T lymphocytes uniquely provide CD8-independent TCR genes for engineering therapeutic T cellsSemantic proximity Read ↗

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

Leukemia relapse via genetic immune escape after allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

CD4(+) T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: association with NY-ESO-1 antibody production.Semantic proximity Read ↗

A pilot trial using lymphocytes genetically engineered with an NY-ESO-1-reactive T-cell receptor: long-term follow-up and correlates with response.Semantic proximity Read ↗

Identification of NY-ESO-1 epitopes presented by human histocompatibility antigen (HLA)-DRB4*0101-0103 and recognized by CD4(+) T lymphocytes of patients with NY-ESO-1-expressing melanoma.Semantic proximity Read ↗

Adoptive T cell therapy promotes the emergence of genomically altered tumor escape variantsSemantic proximity Read ↗

Recurrent genetic HLA loss in AML relapsed after matched unrelated allogeneic hematopoietic cell transplantationSemantic proximity Read ↗

Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma.Semantic proximity Read ↗

One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.